BIOMAT Database Logo BIOMAT Database Logo

Mexiletine therapy in patients with chronic drug-resistant malignant ventricular arrhythmias. Clinical efficacy, safety, and side effects. 1986

D L Haggman, and J D Maloney, and V A Morant, and L W Castle, and M King-Rankine, and M Goormastic

UI MeSH Term Description Entries
D008297 Male Males
D008801 Mexiletine Antiarrhythmic agent pharmacologically similar to LIDOCAINE. It may have some anticonvulsant properties. KO-1173,KO1173,KOE-1173,Mexiletene,Mexiletine Hydrochloride,Mexitil,Mexitil PL,Mexityl,Novo-Mexiletine,KO 1173,KOE 1173,KOE1173,Novo Mexiletine
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009325 Nausea An unpleasant sensation in the stomach usually accompanied by the urge to vomit. Common causes are early pregnancy, sea and motion sickness, emotional stress, intense pain, food poisoning, and various enteroviruses.
D011437 Propylamines Derivatives of propylamine (the structural formula NH2CH2CH2CH3).
D002908 Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2). Chronic Condition,Chronic Illness,Chronically Ill,Chronic Conditions,Chronic Diseases,Chronic Illnesses,Condition, Chronic,Disease, Chronic,Illness, Chronic
D003645 Death, Sudden The abrupt cessation of all vital bodily functions, manifested by the permanent loss of total cerebral, respiratory, and cardiovascular functions. Sudden Death
D004244 Dizziness An imprecise term which may refer to a sense of spatial disorientation, motion of the environment, or lightheadedness. Lightheadedness,Orthostasis,Dizzyness,Light-Headedness,Light Headedness
D004351 Drug Resistance Diminished or failed response of an organism, disease or tissue to the intended effectiveness of a chemical or drug. It should be differentiated from DRUG TOLERANCE which is the progressive diminution of the susceptibility of a human or animal to the effects of a drug, as a result of continued administration. Resistance, Drug
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug

Related Publications

D L Haggman, and J D Maloney, and V A Morant, and L W Castle, and M King-Rankine, and M Goormastic
Mexiletine. Long-term efficacy and side effects in patients with chronic drug-resistant potentially lethal ventricular arrhythmias.
February 1990, Archives of internal medicine,
D L Haggman, and J D Maloney, and V A Morant, and L W Castle, and M King-Rankine, and M Goormastic
Mexiletine therapy in 15 patients with drug-resistant ventricular tachycardia.
March 1980, The American journal of cardiology,
D L Haggman, and J D Maloney, and V A Morant, and L W Castle, and M King-Rankine, and M Goormastic
Evaluation of the antiarrhythmic efficacy of mexiletine in patients with chronic ventricular arrhythmias.
January 1980, Acta cardiologica. Supplementum,
D L Haggman, and J D Maloney, and V A Morant, and L W Castle, and M King-Rankine, and M Goormastic
Chronic mexiletine therapy for suppression of ventricular arrhythmias.
March 1988, Clinical cardiology,
D L Haggman, and J D Maloney, and V A Morant, and L W Castle, and M King-Rankine, and M Goormastic
Mexiletine in the treatment of resistant ventricular arrhythmias: enhancement of efficacy and reduction of dose-related side effects by combination with quinidine.
May 1983, Circulation,
D L Haggman, and J D Maloney, and V A Morant, and L W Castle, and M King-Rankine, and M Goormastic
Tocainide for drug-resistant ventricular arrhythmias: efficacy, side effects, and lidocaine responsiveness for predicting tocainide success.
December 1980, American heart journal,
D L Haggman, and J D Maloney, and V A Morant, and L W Castle, and M King-Rankine, and M Goormastic
Comparative study of the antiarrhythmic efficacy of mexiletine and disopyramide in patients with chronic ventricular arrhythmias.
January 1982, Journal of cardiovascular pharmacology,
D L Haggman, and J D Maloney, and V A Morant, and L W Castle, and M King-Rankine, and M Goormastic
Clinical efficacy and electrophysiologic effects of cibenzoline therapy in patients with ventricular arrhythmias.
March 1984, Journal of the American College of Cardiology,
D L Haggman, and J D Maloney, and V A Morant, and L W Castle, and M King-Rankine, and M Goormastic
Mexiletine in the treatment of resistant ventricular arrhythmias.
December 1996, Circulation,
D L Haggman, and J D Maloney, and V A Morant, and L W Castle, and M King-Rankine, and M Goormastic
[Therapy of drug-resistant ventricular arrhythmias].
November 1986, Fortschritte der Medizin,
Copied contents to your clipboard!